GUIDED THERAPEUTICS INC Cash and Equivalents

Quick Answer

GUIDED THERAPEUTICS INC reported Cash and Equivalents of $2.31 million for fiscal year 2022.

GUIDED THERAPEUTICS INC Cash and Equivalents — Annual History

Fiscal Year Cash and Equivalents YoY Change
2022 $2.31M +259.7%
2021 $643.0K +253.3%
2020 $182.0K -79.8%
2019 $899.0K
2018 $0.00 -100.0%
2017 $1.0K -92.9%
2016 $14.0K -60.0%
2015 $35.0K -78.4%
2014 $162.0K -73.6%
2013 $613.0K -41.3%
2012 $1.04M -52.5%
2011 $2.20M -32.7%
2010 $3.27M +1320.9%
2009 $230.0K

Quarterly Cash and Equivalents

Quarter Ending Cash and Equivalents YoY QoQ
September 30, 2023 $731.0K -72.9% -46.2%
June 30, 2023 $1.36M +204.5% -26.1%
March 31, 2023 $1.84M +153.4% -20.6%
December 31, 2022 $2.31M +259.7% -14.2%
September 30, 2022 $2.70M +398.5% +504.7%
June 30, 2022 $446.0K -51.6% -38.5%
March 31, 2022 $725.0K -41.9% +12.8%
December 31, 2021 $643.0K +253.3% +18.9%
  • GUIDED THERAPEUTICS INC showed an increase of +259.7% in Cash and Equivalents compared to the prior fiscal year.
  • Over the 2009–2022 period, GUIDED THERAPEUTICS INC’s cash and equivalents has grown by 905.7% (from $230.0 thousand to $2.31 million).
  • The most recent figure is from GUIDED THERAPEUTICS INC’s fiscal year 2022 report (Form 10-K), filed with the SEC on March 30, 2023.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment